CLASS ACTION UPDATE for BSX, PEN and GDRX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / January 31, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
BSX Shareholders Click Here: https://www.zlk.com/pslra-1/boston-scientific-corporation-loss-submission-form?prid=12563&wire=1
PEN Shareholders Click Here: https://www.zlk.com/pslra-1/penumbra-inc-information-request-form?prid=12563&wire=1
GDRX Shareholders Click Here: https://www.zlk.com/pslra-1/goodrx-holdings-inc-loss-submission-form?prid=12563&wire=1
* ADDITIONAL INFORMATION BELOW *
Boston Scientific Corporation (NYSE:BSX)
BSX Lawsuit on behalf of: investors who purchased April 24, 2019 - November 16, 2020
Lead Plaintiff Deadline : February 2, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/boston-scientific-corporation-loss-submission-form?prid=12563&wire=1
According to the filed complaint, during the class period, Boston Scientific Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) the LOTUS Edge Aortic Valve System's product delivery system was dysfunctional and threatened the continued viability of the entire product line; (ii) as a result, the Company had materially overstated the continued commercial viability and profitability of the LOTUS Edge Aortic Valve System; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Penumbra, Inc. (NYSE:PEN)
PEN Lawsuit on behalf of: investors who purchased August 3, 2020 - December 15, 2020
Lead Plaintiff Deadline : March 16, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/penumbra-inc-information-request-form?prid=12563&wire=1
According to the filed complaint, during the class period, Penumbra, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) that the Jet 7 Xtra Flex had known design defects that made it unsafe for its normal use; (2) that Penumbra did not adequately address the risk of the Jet 7 Xtra Flex causing serious injury and deaths, which had in fact already occurred; (3) that the Jet 7 Xtra Flex was likely to be recalled due to its safety issues; and (4) as a result, Penumbra's public statements as set forth above were materially false and misleading at all relevant times.
GoodRx Holdings, Inc (NASDAQ:GDRX)
GDRX Lawsuit on behalf of: investors who purchased September 23, 2020 - November 16, 2020
Lead Plaintiff Deadline : February 16, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/goodrx-holdings-inc-loss-submission-form?prid=12563&wire=1
According to the filed complaint, during the class period, GoodRx Holdings, Inc made materially false and/or misleading statements and/or failed to disclose that: at the time of the IPO, unbeknownst to investors, Amazon.com, Inc. was developing and would soon introduce its own online and mobile prescription medication ordering and fulfillment service that would directly compete with GoodRx. Defendants timed the IPO so that it was priced before Amazon announced its online pharmaceutical business to facilitate the IPO and create artificial demand for the common shares sold therein, as well to maximize the amount of money the Company and the selling stockholders could raise in the IPO. Given defendants' knowledge of Amazon's intention to enter the online pharmaceutical business, and their misleading statements about GoodRx's competitive position made contemporaneously with that knowledge, defendants' materially false and/or misleading statements alleged herein were made willfully and caused GoodRx common stock to trade at artificially inflated prices during the Class Period.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/626932/CLASS-ACTION-UPDATE-for-BSX-PEN-and-GDRX-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders
